Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

The United States has passed peak obesity, according to new data, suggesting that the sweeping uptake of weight-loss drugs ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

A weight loss and diabetes drug remains in a shortage. But for the last month, San Ysidro Pharmacy has been supplying ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...